CO4930304A1 - Beta-lipotropina y usos de la misma - Google Patents

Beta-lipotropina y usos de la misma

Info

Publication number
CO4930304A1
CO4930304A1 CO98075718A CO98075718A CO4930304A1 CO 4930304 A1 CO4930304 A1 CO 4930304A1 CO 98075718 A CO98075718 A CO 98075718A CO 98075718 A CO98075718 A CO 98075718A CO 4930304 A1 CO4930304 A1 CO 4930304A1
Authority
CO
Colombia
Prior art keywords
amino acid
beta
lipotropin
seq
peptide
Prior art date
Application number
CO98075718A
Other languages
English (en)
Inventor
John Edward Hale
William Francis Heath
Mark Louis Heiman
Brigitte Elisabeth Schoner
Jon Paul Butler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4930304A1 publication Critical patent/CO4930304A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/67Lipotropins, e.g. beta, gamma lipotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Una proteína de fusión de Beta-lipotropina sustancialmentepura que tiene una secuencia de aminoácidos seleccionada entre el grupo constituido por la SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:6 y SEQ ID NO:7. Un método sintético en fase sólida para la síntesis de beta-lipotropina que comprende los pasos de (a) activación de un aminoácido que tiene su grupo a-amino y como alternativa, la cadena lateral protegida, formándose un éster reactivo; (b) la unión de dicho aminoácido a un soporte sólido inerte, (c) la activación de un segundo aminoácido protegido, en el que el grupo a-amino del primer aminoácido está desprotegido rindiendo una amina reactiva y el segundo aminoácido activado reacciona con dicho primer aminoácido formando un dipéptido sobre el soporte sólido, (d) la repetición de los pasos (a) a (c); (2) la separación del péptido del soporte sólido y la desprotección de las cadenas laterales, (f) la purificación del péptido mediante cualquier medio apropiado; en el que (g) si la secuencia de beta lipotropina contiene un segmento tripeptídico ser-pro-pro, se realiza un acoplamiento doble de los residuos pro y ser; (h) después de completar el paso de acoplamiento, cualquier péptido desprotegido que no ha reaccionado se bloquea con anhídrido acético para evitar el alargamiento de la cadena de un péptido con deleción; y(i) si la secuencia de beta-lipotropina contiene una secuencia dipeptídica de asp-gly, se utiliza una protección N-a-hmb(N-a-(2-hidroxi-4-metoxibencilo)) de cada residuo de glicina que preceda a un residuo de asp.
CO98075718A 1997-12-23 1998-12-21 Beta-lipotropina y usos de la misma CO4930304A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6865997P 1997-12-23 1997-12-23
US7985798P 1998-03-30 1998-03-30
US8632198P 1998-05-21 1998-05-21
US9138598P 1998-07-01 1998-07-01
US9540598P 1998-08-05 1998-08-05
US10397698P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
CO4930304A1 true CO4930304A1 (es) 2000-06-27

Family

ID=27557000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075718A CO4930304A1 (es) 1997-12-23 1998-12-21 Beta-lipotropina y usos de la misma

Country Status (18)

Country Link
US (2) US6323178B1 (es)
EP (1) EP0926239A3 (es)
JP (1) JP2001526061A (es)
KR (1) KR20010024805A (es)
CN (1) CN1284882A (es)
AR (1) AR018532A1 (es)
AU (1) AU1938599A (es)
BR (1) BR9814433A (es)
CA (1) CA2315888A1 (es)
CO (1) CO4930304A1 (es)
EA (1) EA200000709A1 (es)
HR (1) HRP20000426A2 (es)
HU (1) HUP0100132A2 (es)
IL (1) IL136514A0 (es)
PE (1) PE20000062A1 (es)
PL (1) PL341293A1 (es)
TR (1) TR200002611T2 (es)
WO (1) WO1999032142A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503106A (ja) * 2000-12-13 2005-02-03 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
US8227194B2 (en) * 2005-04-08 2012-07-24 University Of Maryland, Baltimore Monoclonal antibodies with binding specificity for response gene to complement 32 (RGC-32)
US20090281519A1 (en) * 2008-05-12 2009-11-12 Rao R Harsha Automated system and method for diabetes control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
JP3822232B2 (ja) * 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来dna合成阻害因子
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins

Also Published As

Publication number Publication date
PL341293A1 (en) 2001-04-09
AR018532A1 (es) 2001-11-28
HUP0100132A2 (hu) 2001-05-28
US20030073621A1 (en) 2003-04-17
PE20000062A1 (es) 2000-02-08
WO1999032142A1 (en) 1999-07-01
CN1284882A (zh) 2001-02-21
JP2001526061A (ja) 2001-12-18
EA200000709A1 (ru) 2000-12-25
EP0926239A3 (en) 2002-08-28
BR9814433A (pt) 2000-10-10
KR20010024805A (ko) 2001-03-26
EP0926239A2 (en) 1999-06-30
TR200002611T2 (tr) 2000-12-21
HRP20000426A2 (en) 2000-10-31
US6323178B1 (en) 2001-11-27
AU1938599A (en) 1999-07-12
IL136514A0 (en) 2001-06-14
CA2315888A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
Kawakami et al. Peptide thioester preparation based on an NS acyl shift reaction mediated by a thiol ligation auxiliary
ES2239364T3 (es) Sintesis de peptidos en fase solida.
ES2334106T3 (es) Inhibidores peptidos de fusion de larga vida contra infecciones virales.
SU1651787A3 (ru) Способ получени полипептида, обладающего свойствами фактора высвобождени гормона роста
Penke et al. Solid-phase synthesis of peptide amides on a polystyrene support using fluorenylmethoxycarbonyl protecting groups
CO5040054A1 (es) Metodo para preparar y purificar un derivado de aspartame n-alquilatado
DE69737415D1 (de) Gespannte, helixformende peptide und verfahren um sie herzustellen
ES2181799T3 (es) Conjugados de acidos peptido nucleicos.
ES2192620T3 (es) Polipeptido receptor de il-13.
RU2010128247A (ru) Синтез инсулинотропных пептидов с помощью комбинированных твердофазных и растворных методик
CO4930304A1 (es) Beta-lipotropina y usos de la misma
AR002798A1 (es) Nuevos procedimientos para la preparacion de peptidos y de peptidos n-carbamoil protegidos y el empleo de aspartamo como edulcorante.
ES2310993T3 (es) Metodo de sintesis de peptidos en fase solida.
AR020066A1 (es) Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican
KR850000469A (ko) hp GRF(소마토크리닌)의 합성방법
DK0794255T3 (da) Fremgangsmåde til spaltning af kimært protein ved anvendelse af processeringsenzym
US9850274B2 (en) Peptide combination
NZ334486A (en) Preparation of purified (poly) peptides utilising a cleavable amino acid inserted into the polypeptide chain during synthesis
RU2001126541A (ru) Способ получения цикло(Asp-DPhe-NmeVal-arg-Gly)
GB1532181A (en) Pentapetides and a method of preparing them
DE50015431D1 (de) Membranverankerte gp41-fusionspeptide und deren verwendungen
Fauchere et al. Differential protection and selective deprotection in peptide synthesis
Kiso et al. N in-Diphenylphosphinothioyltryptophan, a useful derivative for peptide synthesis by the methanesulphonic acid–thioanisole system and fluoride ion deprotection methods
Okada et al. Amino acids and peptides. LIV. Application of 2-adamantyl derivatives as protecting groups to the synthesis of peptide fragments related to Sulfolobus solifataricus Ribonuclease. I
Gish Peptide synthesis